Fellow Health Joins Progyny Network to Support Men’s Health Fertility Screening with Mail-In Semen Analysis for Fertility Care

Audio By Carbonatix

SAN LEANDRO, Calif.--(BUSINESS WIRE)--Sep 10, 2025--

Fellow Health, a leading company focused on advancing male reproductive health through patient-centric testing solutions, today announced it is joining the Progyny network to support the growing need for semen analysis as a critical step in the fertility care journey. Fellow Health’s mail-in semen analysis will be a covered benefit for eligible Progyny members, giving patients access to convenient, at-home testing with results equivalent to traditional in-clinic testing.

Male factor infertility plays a role in nearly 50% of all infertility cases, yet in-clinic semen collection remains a major barrier to fertility testing due to its discomfort and inconvenience. Fellow Health addresses this challenge with a mail-in semen analysis kit that prioritizes both privacy and diagnostic quality. Unlike wellness-grade alternatives, Fellow Health’s test is processed by a high-complexity, CLIA-accredited laboratory and delivers clinically actionable results that support diagnosis and treatment planning.

By joining the Progyny network as a lab and ancillary provider, Fellow Health expands access to early fertility testing at a critical point in the care journey. Progyny is a global leader in women’s health and family building, with a network of more than 650 clinics nationwide. By obtaining semen analysis results ahead of the initial fertility consultation—members can engage in more productive, personalized conversations around care that help empower their decision making.

“As individuals embark on their family building journey, the more information they have at the start, the better supported they are in their healthcare decision making,” explained Dr. Janet Choi, Chief Medical Officer, Progyny. “With nearly 50% of fertility cases involving male factor infertility, we advocate that the standard of care should include semen analyses, and we have been seeing more and more men electively embrace their role.”

“At-home collection provides unmatched convenience, but what really matters is delivering clinically meaningful results,” said Dr. James Smith, Chief Medical Officer at Fellow Health. “Fellow Health’s mail-in semen analysis combines the comfort of at-home collection with the quality and accuracy of an in-lab diagnostic test, empowering patients and providers to have more informed, productive conversations from the very first appointment.”

Progyny members can access Fellow Health’s test by contacting their Progyny Care Advocates (PCAs) directly to initiate an order. To learn more, visit www.meetfellow.com.

About Fellow Health

Founded in 2018, Fellow Health is a leading company dedicated to advancing male reproductive health through innovative and comprehensive mail-in testing solutions. The company partners with more than 2,000 top clinical practices, processing over 400 patient samples daily through its CLIA-certified lab, and is the only mail-in semen analysis with peer-reviewed validation data. Fellow Health has secured funding from leading life sciences and technology investors, including 5AM Ventures, Forest Road, Labcorp Venture Fund, Human Capital, Genoa Ventures, and Mantis Venture Capital.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250910972757/en/

CONTACT: Media Contact:

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BABY/MATERNITY HEALTH GENERAL HEALTH WOMEN MEN OTHER SCIENCE RESEARCH FAMILY CONSUMER SCIENCE PARENTING

SOURCE: Fellow Health

Copyright Business Wire 2025.

PUB: 09/10/2025 10:00 AM/DISC: 09/10/2025 09:59 AM

http://www.businesswire.com/news/home/20250910972757/en